Welcome to our dedicated page for Beam Therapeutics news (Ticker: BEAM), a resource for investors and traders seeking the latest updates and insights on Beam Therapeutics stock.
Beam Therapeutics Inc. (Nasdaq: BEAM) generates frequent news as a biotechnology company developing precision genetic medicines through base editing. News about BEAM stock often centers on clinical data readouts, regulatory designations and strategic updates across its hematology and liver-targeted genetic disease franchises.
Investors following BEAM news can expect detailed updates on risto-cel (formerly BEAM-101), an investigational ex vivo base editing cell therapy for sickle cell disease with severe vaso-occlusive crises. The company regularly reports safety and efficacy data from the BEACON Phase 1/2 trial, including measures such as fetal hemoglobin induction, reductions in sickle hemoglobin, engraftment times and markers of hemolysis, as well as designations like RMAT and orphan drug status from the U.S. Food and Drug Administration.
Another major source of headlines is BEAM-302, Beam’s liver-targeting program for alpha-1 antitrypsin deficiency (AATD). Company press releases describe Phase 1/2 trial progress, dose exploration, evidence of in vivo genetic correction of a disease-causing mutation, restoration of functional alpha-1 antitrypsin and regulatory interactions, including RMAT designation, orphan drug designation and participation in the FDA’s CDRP program.
Additional BEAM news items highlight developments in BEAM-301 for glycogen storage disease type Ia, the ESCAPE platform and BEAM-103 antibody, targeted lipid nanoparticle delivery research, financial results, cash runway commentary and participation in scientific and investor conferences. Coverage may also reference Beam’s equity stake in Orbital Therapeutics and the impact of Orbital’s acquisition by Bristol Myers Squibb, as disclosed by the company.
For readers tracking BEAM, this news feed provides ongoing insight into Beam’s clinical milestones, regulatory pathways, platform evolution and corporate transactions that shape the outlook for its precision genetic medicines pipeline.
Beam Therapeutics Inc. (Nasdaq: BEAM) announced that CEO John Evans will participate in a fireside chat at the SVB Leerink 11th Annual Global Healthcare Conference on February 16, 2022, at 9:20 a.m. ET. A live webcast will be available on their investor website and archived for 60 days. Beam Therapeutics specializes in precision genetic medicines using base editing technology, targeting precise genetic changes without damaging DNA. The company aims to create life-long cures for serious diseases through advanced gene editing and manufacturing capabilities.
Beam Therapeutics and Pfizer have entered a four-year collaboration aimed at developing precision genetic medicines for rare genetic diseases. This partnership will leverage Beam's base editing and delivery technologies, combining them with Pfizer's expertise in drug development. Beam will receive an upfront payment of $300 million and is eligible for milestone payments totaling up to $1.35 billion. The collaboration will focus on three undisclosed targets, with the possibility for co-development and commercialization of one program.
Pfizer (PFE) and Beam Therapeutics (BEAM) announced a four-year research collaboration to develop in vivo base editing programs targeting rare genetic diseases. Beam will receive an upfront payment of
Beam Therapeutics (Nasdaq: BEAM) has announced significant milestones for 2022, including the anticipated enrollment of the first subject in the BEAM-101 Phase 1/2 clinical trial for sickle cell disease in the second half of the year. The company introduced BEAM-301 as its fourth development candidate aimed at treating Glycogen Storage Disease Type Ia. Other key developments involve plans to nominate two additional candidates and present business updates at the J.P. Morgan Healthcare Conference on January 10, 2022. Beam focuses on pioneering precision genetic medicines through base editing technology.
Beam Therapeutics (Nasdaq: BEAM), a biotechnology firm specializing in precision genetic medicines, has announced that CEO John Evans will present at the 40th Annual J.P. Morgan Healthcare Conference on January 10, 2022, at 2:15 p.m. ET. The presentation will be accessible via live webcast on the company's investor website, with an archive available for 60 days post-event.
Beam is focused on developing gene editing technologies, particularly base editing, which allows for precise genetic alterations without DNA breaks, aiming to provide innovative treatments for serious diseases.
Beam Therapeutics (Nasdaq: BEAM) has introduced a comprehensive three-stage strategy for developing its base editing therapies targeting sickle cell disease (SCD). This plan, presented at the 63rd American Society for Hematology Annual Meeting, emphasizes advancements in ex vivo programs BEAM-101 and BEAM-102, improved patient conditioning, and in vivo editing through lipid nanoparticles. Beam aims to enhance accessibility for SCD treatments, with ongoing clinical trials and promising preclinical data supporting its innovative therapeutic approach.
Beam Therapeutics (Nasdaq: BEAM) announced promising preclinical research showing that multiplex edited CAR T cells effectively target CD5-positive tumors, resulting in tumor clearance in vivo. Presented at the SITC 36th Annual Meeting, key findings include 94-98% editing efficiency across five target loci and significant enhancements in proinflammatory cytokine production, including over a 300% increase in IL-2. This research addresses the unmet need in T-cell malignancy treatments, potentially offering safer, more durable therapies for patients.
CAMBRIDGE, Mass., Nov. 11, 2021 - Beam Therapeutics (Nasdaq: BEAM) announces that CEO John Evans will participate in a fireside chat at the Jefferies 2021 Virtual London Healthcare Conference, held from November 16-19, 2021. The chat is accessible on-demand to registered participants from 8:00 a.m. GMT on November 18 to 5:00 p.m. GMT on November 19, 2021. The webcast will be available in the investor section of the company's website for 60 days post-event.
Beam focuses on precision genetic medicines using base editing technology for therapeutic advancements.
Beam Therapeutics announced FDA clearance for its Investigational New Drug (IND) application for BEAM-101, a treatment for sickle cell disease, marking a significant milestone as the first IND for base editing technology. The company is set to start the BEACON-101 Phase 1/2 trial. Additionally, BEAM-102 IND-enabling studies are underway to develop another gene-editing treatment for sickle cell disease. Financially, Beam reported a net loss of $28.1 million for Q3 2021, down from $34.5 million in Q3 2020, with cash reserves at $933.4 million as of September 30, 2021.
Beam Therapeutics (Nasdaq: BEAM) announced that John Maraganore, former CEO of Alnylam Pharmaceuticals, has joined its board of directors. His experience in building successful biotech companies and drug development programs is expected to enhance Beam's strategic direction. This move comes as Beam prepares to advance its first base editing technology into clinical trials for sickle cell disease. The company has recently received clearance for its Investigational New Drug application for BEAM-101, marking a significant milestone for its transition into a clinical-stage organization.